The World Federation of Hemophilia (WFH) workshop on von Willebrand Disease (VWD) that took place on December 8th, 2018 in Belgrade, Serbia, marked the successful completion of the WFH Global Alliance for Progress (GAP) Program (GAP/2015-2018) in Serbia. The GAP program has advanced the overall organization of care and access to treatment for people with hemophilia and other rare bleeding disorders in the country. This was done through a sustainable increase of the purchase of treatment products, and a strengthening of multi-disciplinary medical expertise in all regions of Serbia.
The GAP Program has helped build the capacity of the Serbian Hemophilia Society in the country to support women, youth, parents and VWD peer-to-peer support groups.
The WFH would like to extend its sincere gratitude to the dedicated work of the volunteers of the Serbian Hemophilia Society (SHS), the Hemophilia Treatment Centers in Belgrade, Novi Sad and Nis, the National Registry of Inherited Bleeding Disorders of Serbia and national authorities for their valuable contributions in realizing the GAP Program in Serbia.
The GAP Program is supported by funding from: Bayer, Biogen, Biotest, CSL Behring, Grifols, Kedrion, Novo Nordisk, Pfizer, Shire, and SOBI.